Diabetic ketoacidosis is a worrying complication associated with the use of sodium/glucose cotransporter 2 (SGLT2) inhibitors in patients with type 1 diabetes mellitus (T1DM) or T2DM. A recent ...

No difference in insulin discontinuation rates seen among three glucose-lowering classes ...

Patients with chronic kidney disease and type 2 diabetes receiving pharmacist-led outreach were nearly twice as likely to start an SGLT2 inhibitor as those receiving usual care.

The SGLT2 inhibitors market is experiencing robust growth, driven by the rising prevalence of type 2 diabetes and chronic kidney disease worldwide. Additionally, the expected launch of emerging SGLT2 ...

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) may be prescribed to people with heart failure, chronic kidney disease, ...

CHICAGO — For older patients at high risk for a heart failure event who are scheduled for transcatheter aortic valve implantation (TAVI), dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) ...

SGLT2 inhibitor use linked to reduced odds of all-cause dementia, psychiatric ED visits in intention-to-treat analysis.

SGLT2 inhibitor use also correlated with lower rates of psychiatric ED visits ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in patients ...

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...

The U.S. SGLT2 Inhibitors Market is projected to grow from USD 5.49 Billion in 2025 to USD 11.06 Billion by 2035, while ...